TY - JOUR
T1 - Updates in the management of early-stage diffuse large b-cell lymphoma
AU - Habermann, Thomas M.
N1 - Publisher Copyright:
© 2021 Harborside Press. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Several important updates have emerged in the management of early-stage diffuse large B-cell lymphoma. Three trials resulted in the approval of rituximab 1 cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) for use in these patients internationally. Furthermore, studies have been initiated to determine whether 4 or 6 cycles of this regimen should be administered without radiation therapy (RT). Six cycles of R-CHOP plus central nervous system (CNS) prophylaxis and prophylactic testicular RT are recommended for patients with extranodal disease occupying the testicles. Although controversial, there is a reasonable consensus in the literature to consider 6 cycles of R-CHOP plus involved-site RT and CNS prophylaxis for patients with extranodal disease of the breast. Patients with primary bone and gastric extranodal disease do not seem to derive a significant survival benefit fromRT.Molecular subtype evaluationsmay change treatment approaches.
AB - Several important updates have emerged in the management of early-stage diffuse large B-cell lymphoma. Three trials resulted in the approval of rituximab 1 cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) for use in these patients internationally. Furthermore, studies have been initiated to determine whether 4 or 6 cycles of this regimen should be administered without radiation therapy (RT). Six cycles of R-CHOP plus central nervous system (CNS) prophylaxis and prophylactic testicular RT are recommended for patients with extranodal disease occupying the testicles. Although controversial, there is a reasonable consensus in the literature to consider 6 cycles of R-CHOP plus involved-site RT and CNS prophylaxis for patients with extranodal disease of the breast. Patients with primary bone and gastric extranodal disease do not seem to derive a significant survival benefit fromRT.Molecular subtype evaluationsmay change treatment approaches.
UR - http://www.scopus.com/inward/record.url?scp=85120628104&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120628104&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2021.5108
DO - 10.6004/jnccn.2021.5108
M3 - Article
AN - SCOPUS:85120628104
SN - 1540-1405
VL - 19
SP - 1324
EP - 1326
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
ER -